Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
about
Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factorsPrognostic biomarkers to identify patients destined to develop severe Crohn's disease who may benefit from early biological therapy: protocol for a systematic review, meta-analysis and external validation.Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.Perianal Crohn's disease: challenges and solutions.Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Preventing Collateral Damage in Crohn's Disease: The Lémann Index.Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.Top-down approach to biological therapy of Crohn's disease.Practical Approaches to "Top-Down" Therapies for Crohn's Disease.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Next-Generation Therapeutics for Inflammatory Bowel Disease.Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort.Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Preventing disability in inflammatory bowel disease.Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Validity of Contrast-enhanced Ultrasonography and Dynamic Contrast-enhanced MR Enterography in the Assessment of Transmural Activity and Fibrosis in Crohn's Disease.Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target.Changing treatment paradigms for the management of inflammatory bowel disease.The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management.Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies.Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients.Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease.Inflammatory bowel disease: towards a personalized medicine.Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine.Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.IBD: Step-up vs top-down therapy for Crohn's disease: medicine vs surgery.Diagnostic Delay in Crohn's Disease: Time for Red Flags.Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort.Precision Medicine in Inflammatory Bowel Diseases.
P2860
Q36380315-A04465FD-1FF8-4B7F-A90D-F9B8982F933EQ37460415-536F4CAA-376F-40EF-A405-061CEE5480D0Q37521805-EB22BC5B-230E-4D7F-AD54-6907D5A7EFBEQ37641311-A997EC95-2692-44BC-9827-18636B542852Q38608939-19127C95-01EE-4878-A3AA-802CCD1FC51FQ38673082-0BAF3057-132C-4A77-9039-D6BC7133A918Q38690180-32D617DE-27A4-404E-B371-A56F5C92D109Q38706667-8D949268-E252-4F69-9987-9BD281D6FE97Q38707864-6500F993-6AFE-4981-870D-90692759D27AQ38726458-2D3C768B-987D-44EF-8D9C-21116CFC2ED2Q38752119-02C25744-68D2-4EEA-B31D-5A33EE2C43C0Q38764671-E1767D60-A62D-4667-830E-5425A6CE39EFQ38835478-FB4D294F-4684-41C6-9AF1-1B68346F5D70Q38850063-077FEB6A-1601-4CD7-BDCF-8B6252DCCABEQ38909523-EB740F1A-8367-4581-981B-B0153EBB932BQ39353122-63AC1676-84C1-4E05-81DB-057D52BD3222Q40503775-71AC959E-55CB-4E96-91DD-A6B159C1EFD1Q40515016-6EF3EE15-414F-4FBD-AA3E-941D2610C6EBQ44581309-DB90E37E-043A-4D83-8A42-2A78A9725F17Q45338711-65B44637-31AC-4D36-9B4D-82FC335E0C3AQ46027208-BBC7CEE6-2E84-43D1-8885-9090A9117CB6Q46303978-A669D2E3-5B83-48EF-8ED5-4BEBAAF909E8Q47109861-0D35F48E-D193-4C06-BA2D-675F0E88C370Q47598080-A0E3AFE1-625A-4ABB-ACF3-3F621B350E52Q48017823-20246403-2763-4571-ACDC-EB5CD1DA42E4Q48125489-BA3E0B9A-9ABE-4130-A50F-8FFB362799E0Q48191965-2BA8C7AD-97F5-4E51-B0CE-019352EC57D8Q48518781-447AC7E5-9BBF-4E31-B812-FE036BDEADC5Q48537463-23358D54-D269-4F1A-A3E1-04C387B42F98Q48579378-73D09E1E-B15B-4A23-B43A-CC58934A5626Q48680314-11DA0C1F-C58E-4DF7-B947-638887E09966Q49339951-9E924904-2ADF-4D61-A6F7-054338B9ECEAQ49427029-122E47DD-1100-4B2A-B199-E270E1A6DF2EQ49570157-2E091BAE-236E-4607-A26F-2D0C8172751FQ50036719-C79F36B5-25DC-44E9-A771-75250E59AA95Q50037387-DA5E3DDD-7AFA-4B7D-8C21-3A092D8BF742Q50091514-7C256B66-B39F-499F-857D-1F699DE10226Q50226946-ECB99B7B-29BB-4113-8BA3-E8D0170691D8Q50578123-B2C8AAF5-E657-411C-8D94-013F07DA6EDAQ51828636-68D99DC9-D18E-4DC2-97AD-290A897BAAF7
P2860
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Early combined immunosuppressi ...... r randomised controlled trial.
@en
type
label
Early combined immunosuppressi ...... r randomised controlled trial.
@en
prefLabel
Early combined immunosuppressi ...... r randomised controlled trial.
@en
P2093
P1433
P1476
Early combined immunosuppressi ...... r randomised controlled trial.
@en
P2093
Alain Bitton
Allan Donner
Barrett G Levesque
Brian Bressler
Donald MacIntosh
Geert D'Haens
Gordon R Greenberg
Guangyong Zou
Joan C Morris
Larry W Stitt
P304
P356
10.1016/S0140-6736(15)00068-9
P407
P577
2015-09-02T00:00:00Z